Sun Pharma begins phase II clinical trial on dengue drug for Covid-19

This is the first phytopharmaceutical drug (plant based) that the country's drug regulator has approved for clinical trials for Covid-19.

India's largest drugmaker Sun Pharmaceutical Industries said on Friday that it has commenced phase II clinical trials on AQCH, a plant-derived drug that was originally developed for dengue, to see if it can potentially treat Covid-19.
 

The trial will be conducted across 12 centres in India on 210 patients. This is also the first phytopharmaceutical drug (plant based) that the country's drug regulator has approved for clinical trials for Covid-19. The company said that the results of the trial are expected by October this year. “Human safety study of AQCH has already been completed and the drug has been found